- Kebotix — AI-driven materials discovery platform that runs closed-loop robotic experiments for chemicals and polymers.
Why it fits: Harvard spin-out; raised seed/Series A from deep-tech funds; active industrial partnerships in materials.
- LabGenius — Autonomous antibody discovery platform (EVA) combining machine learning with robotic wet-lab testing to evolve therapeutic proteins.
Why it fits: Series B stage; multi-target pharma collaborations validate closed-loop protein engineering.
- Chemify — Building programmable chemistry infrastructure (“chemputation”) to automate molecular synthesis and discovery.
Why it fits: Founded by Lee Cronin; significant UK/VC backing; early but high-signal effort to make chemistry a programmable, autonomous discipline.
- Atinary Technologies — AI/ML platform that turns lab instruments into self-driving labs via real-time experiment optimization.
Why it fits: EPFL spin-out; deployed with chemicals and materials corporates; early revenue and strong technical team.
- Arctoris — Robotic laboratory-as-a-service for automated drug discovery experiments, generating reproducible, high-quality data.
Why it fits: Series A; partnerships with biotech/pharma in oncology and CNS; demonstrates autonomous experimentation as a service.
- Strateos — Cloud-based robotic lab platform for remote, programmable experimentation across biology and chemistry.
Why it fits: Formed from Transcriptic/3Scan merger; enterprise and government contracts; proven cloud-lab model.
- Emerald Cloud Lab — Cloud laboratory that lets scientists run automated experiments remotely using code.
Why it fits: Used by academic centers and biotech; established but still expanding autonomy/AI features; key infrastructure for self-driving labs.
- Synthace — Experiment design and automation software (“Antha”) enabling reproducible, data-rich biological workflows.
Why it fits: Early-ish company with pharma/ag partnerships; its software layer is a critical enabler for closing the loop in biology labs.
- Odyssey Therapeutics — Bio company building a self-driving drug discovery engine spanning AI, biology, chemistry, and automation.
Why it fits: Founded 2020; large Series C; rapid pipeline growth; less-known than Insitro but strong internal autonomy stack.
- Insitro — AI-driven drug discovery with an in-house automated laboratory generating high-content data for machine learning.
Why it fits: Raised >$600M; partnerships with Gilead/BMS; late-stage but a benchmark for autonomous biology at scale.
White-space gaps noticed while sourcing:
- Formulation and complex-mixture self-driving labs — most startups target drug discovery or advanced materials; food, agchem, personal care, and consumer products with sensory/rheological properties remain underserved.
- General-purpose robotic manipulation that retrofits legacy instruments — current platforms often require standardized liquid handling or purpose-built hardware; a layer that handles messy, real-world lab operations (powders, viscous fluids, heterogeneous samples) on existing instruments would unlock much broader adoption.